Evidence map›Paper›PMID 37456251›Full record

ArticleFrontiers in oncology2023

Radiation-induced lung injury after breast cancer treatment: incidence in the CANTO-RT cohort and associated clinical and dosimetric risk factors.

Anna Gueiderikh, Thomas Sarrade, Youlia Kirova, Brigitte De La Lande, Florent De Vathaire, Guillaume Auzac, Anne Laure Martin, Sibille Everhard, Nicolas Meillan, Celine Bourgier and 11 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01993498 (A Prospective Cohort to Investigate Survivorship Issues in Patients With Early Cancer), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01993498 narecruitingnot on this map

A Prospective Cohort to Investigate Survivorship Issues in Patients With Early Cancer

TypeinterventionalSponsorUNICANCERRan2012 to 2034Enrolled14,750ConditionsBreast Cancer Nos Metastatic Recurrent, Early Lung CancerArmsblood sampling
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 14 institutions in 1 country.

Anna GueiderikhGustave Roussy, Radiation Therapy Department, Villejuif, France.
Thomas SarradeTenon Hospital, Radiotherapy Department, Paris, France.
Youlia KirovaDepartment of Radiation Oncology, Institut Curie, Paris, France.
Brigitte De La LandeDepartment of Radiation Oncology, Institut Curie, Saint Cloud, France.
Florent De VathaireGustave Roussy, Comprehensive Cancer Research Center, Villejuif, France.
Guillaume AuzacGustave Roussy, Radiation Therapy Department, Villejuif, France.
Anne Laure MartinUNICANCER, Data Department, Kremlin Bicêtre, France.
Sibille EverhardUNICANCER, Data Department, Kremlin Bicêtre, France.
Nicolas MeillanCentre for Research in Epidemiology and Population Health, U1018 Institut National de la Santé et de la Recherche Médicale (INSERM), Villejuif, France.
Celine BourgierMontpellier University, Montpellier, France.
Ahmed BenyoucefRadiation Therapy Department, Henri Becquerel Center, Rouen, France.
Thomas LacornerieCentre Oscar Lambret, Academic Department of Radiation Oncology, 3 rue Combemale, Lille, France.
David PasquierCentre Oscar Lambret, Academic Department of Radiation Oncology, 3 rue Combemale, Lille, France.
Séverine RacadotRadiotherapy Department, Centre Léon Bérard, Lyon, France.
Alexandra MoignierRadiotherapy Department, Institut de Cancérologie de l'Ouest, Nantes, France.
François ParisRadiotherapy Department, Institut de Cancérologie de l'Ouest, Nantes, France.
Fabrice AndréGustave Roussy, Medical Oncology Department, Villejuif, France.
Eric DeutschGustave Roussy, Radiation Therapy Department, Villejuif, France.
Boris DuchemannAvicenne Hospital, Thoracic Oncology, Bobigny, France.
Rodrigue Setcheou AllodjiGustave Roussy, Comprehensive Cancer Research Center, Villejuif, France.
Sofia RiveraGustave Roussy, Radiation Therapy Department, Villejuif, France.
Inserm · FRCentre de recherche en Epidémiologie et Santé des Populations · FRInstitut Gustave Roussy · FRUniCancer Group · FRCentre Léon Bérard · FRCentre National de la Recherche Scientifique · FRCentre Oscar Lambret · FRHôpital Avicenne · FRInstitut Curie · FRInstitut de Cancérologie de l'Ouest · FRSorbonne Université · FRUniversité de Lille · FRUniversité de Montpellier · FRUniversité de Versailles Saint-Quentin-en-Yvelines · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Radiation-induced lung injury (RILI) is strongly associated with various clinical conditions and dosimetric parameters. Former studies have led to reducing radiotherapy (RT) doses to the lung and have favored the discontinuation of tamoxifen during RT. However, the monocentric design and variability of dosimetric parameters chosen have limited further improvement. The aim of our study was to assess the incidence of RILI in current practice and to determine clinical and dosimetric risk factors associated with RILI occurrence. Material and methods: Data from 3 out of the 10 top recruiting centers in CANTO-RT, a subset of the CANTO prospective longitudinal cohort (NCT01993498), were retrospectively analyzed for RILI occurrence. This cohort, which recruited invasive cT0-3 cN0-3 M0 breast cancer patients from 2012 to 2018, prospectively recorded the occurrence of adverse events by questionnaires and medical visits at the end of, and up to 60 months after treatment. RILI adverse events were defined in all patients by the association of clinical symptoms and compatible medical imaging. Results: RILI was found in 38/1565 (2.4%) patients. Grade II RILI represented 15/38 events (39%) and grade III or IV 2/38 events (6%). There were no grade V events. The most frequently used technique for treatment was 3D conformational RT (96%). In univariable analyses, we confirmed the association of RILI occurrence with pulmonary medical history, absence of cardiovascular disease medical history, high pT and pN, chemotherapy use, nodal RT. All dosimetric parameters were highly correlated and had close predictive value. In the multivariable analysis adjusted for chemotherapy use and nodal involvement, pulmonary medical history (OR=3.05, p<0.01) and high V30 Gy (OR=1.06, p=0.04) remained statistically significant risk factors for RILI occurrence. V30 Gy >15% was significantly associated with RILI occurrence in a multivariable analysis (OR=3.07, p=0.03). Conclusion: Our study confirms the pulmonary safety of breast 3D RT in CANTO-RT. Further analyses with modern radiation therapy techniques such as IMRT are needed. Our results argue in favor of a dose constraint to the ipsilateral lung using V30 Gy not exceeding 15%, especially in patients presenting pulmonary medical history. Pulmonary disease records should be taken into account for RT planning.

Indexed as

breast cancerCANTO cohortdosimetric analyseslug fibrosisradiation therapyradio-induced lung injuryRILI

Identifiers

PMID37456251
PMCPMC10342531
OpenAlexW4382788303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.